 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | UBX0101 / Unity Biotech
Preclinical, Journal: Senolytic treatment reduces oxidative protein stress in an aging male murine model of post-traumatic osteoarthritis. (Pubmed Central) - Nov 17, 2023
We find that senolysis by a p53/MDM2 interaction inhibitor, UBX0101, reduces protein oxidative modification in the aged arthritic knee joint...These opposing responses include differing signatures of protein-by-protein oxidative modification and abundance change, disparate quantitative trends in modified protein network centrality, and contrasting patterns of oxidation-induced folding free energy perturbation between young and old. We develop a composite sensitivity score to identify specific key proteins in the proteomes of aged osteoarthritic joints, thereby nominating prospective therapeutic targets to complement senolytics.
- UBX0101 / Unity Biotech
[VIRTUAL] A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis () - May 3, 2021 - Abstract #OARSI2021OARSI_62;
P1
UBX0101 is a p53/MDM2 interaction inhibitor that can induce apoptosis of senescent synoviocytes. Results from a recent Phase 1 study (NCT03513016) suggested that IA UBX0101 had dose-dependent, clinically meaningful effects on pain and function in patients with knee OA.
- |||| UBX0101 / Unity Biotech
Trial completion date, Trial termination, Trial primary completion date: Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo (clinicaltrials.gov) - Nov 16, 2020
P=N/A, N=161, Terminated, Sponsor: Unity Biotechnology, Inc.
Results from a recent Phase 1 study (NCT03513016) suggested that IA UBX0101 had dose-dependent, clinically meaningful effects on pain and function in patients with knee OA. Trial completion date: Jun 2021 --> Nov 2020 | Enrolling by invitation --> Terminated | Trial primary completion date: Jun 2021 --> Nov 2020; Inability to achieve primary or secondary study objectives
- || UBX0101 / Unity Biotech
Trial completion: A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Oct 19, 2020
P1, N=35, Completed, Sponsor: Unity Biotechnology, Inc.
Trial completion date: Jun 2021 --> Nov 2020 | Enrolling by invitation --> Terminated | Trial primary completion date: Jun 2021 --> Nov 2020; Inability to achieve primary or secondary study objectives Active, not recruiting --> Completed
- ||| UBX0101 / Unity Biotech
Trial completion: A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Sep 2, 2020
P2, N=183, Completed, Sponsor: Unity Biotechnology, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || UBX0101 / Unity Biotech
L'un des grands espoirs de nouveau médicament pour l'arthrose, l'UBX0101, molécule sénolytique, échoue en phase 2. https://t.co/5Fw1W33TIG (Twitter) - Aug 17, 2020
- |||||| UBX0101 / Unity Biotech
New trial: Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo (clinicaltrials.gov) - Apr 15, 2020
P, N=180, Enrolling by invitation, Sponsor: Unity Biotechnology, Inc.
- || UBX0101 / Unity Biotech
Enrollment closed: A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Apr 7, 2020
P1, N=35, Active, not recruiting, Sponsor: Unity Biotechnology, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || UBX0101 / Unity Biotech
Enrollment closed: A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Feb 26, 2020
P2, N=183, Active, not recruiting, Sponsor: Unity Biotechnology, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || UBX0101 / Unity Biotech
New P1 trial: A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Jan 15, 2020
P1, N=36, Recruiting, Sponsor: Unity Biotechnology, Inc.
- UBX0101 / Unity Biotech
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4201;
The activity of UBX0101 is supported by its effects on multiple BMKs, as well as the clinically meaningful and durable improvements in pain and function. UBX0101 as a senolytic agent may be an important future therapeutic option for pts with knee OA.
- UBX0101 / Unity Biotech
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4177;
The activity of UBX0101 is supported by its effects on multiple BMKs, as well as the clinically meaningful and durable improvements in pain and function. UBX0101 as a senolytic agent may be an important future therapeutic option for pts with knee OA.
- | UBX0101 / Unity Biotech
New P2 trial: A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Oct 16, 2019
P2, N=180, Recruiting, Sponsor: Unity Biotechnology, Inc.
- ||| UBX0101 / Unity Biotech
Trial completion: A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - May 13, 2019
P1, N=78, Completed, Sponsor: Unity Biotechnology, Inc.
UBX0101 as a senolytic agent may be an important future therapeutic option for pts with knee OA. Active, not recruiting --> Completed
- || UBX0101 / Unity Biotech
Enrollment closed: A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Mar 13, 2019
P1, N=72, Active, not recruiting, Sponsor: Unity Biotechnology, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || UBX0101 / Unity Biotech
Enrollment change, Trial completion date, Trial primary completion date: A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Feb 1, 2019
P1, N=72, Recruiting, Sponsor: Unity Biotechnology, Inc.
Recruiting --> Active, not recruiting N=40 --> 72 | Trial completion date: Nov 2018 --> May 2019 | Trial primary completion date: Nov 2018 --> Apr 2019
- || UBX0101 / Unity Biotech
New P1 trial: A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Apr 30, 2018
P1, N=40, Recruiting, Sponsor: Unity Biotechnology, Inc.